**Core Concept**
Sickle cell anemia is a genetic disorder characterized by the production of abnormal hemoglobin (HbS) due to a point mutation in the HBB gene, leading to polymerization of deoxygenated hemoglobin and red blood cell (RBC) sickling. This results in RBC hemolysis, vaso-occlusion, and chronic anemia.

**Why the Correct Answer is Right**
Hydroxyurea (hydroxycarbamide) is the best treatment for sickle cell anemia, as it increases fetal hemoglobin (HbF) production, which reduces hemolysis and vaso-occlusion. Hydroxyurea acts by increasing the transcription of the gamma-globin gene, leading to increased production of HbF, which is more resistant to polymerization than HbS. This results in improved RBC survival, reduced pain episodes, and decreased need for blood transfusions.

**Why Each Wrong Option is Incorrect**
**Option A:** Blood transfusions are a temporary measure to increase RBC count but do not address the underlying genetic defect and can lead to iron overload.
**Option B:** Folic acid is essential for erythropoiesis, but it does not specifically target the sickling process.
**Option C:** Penicillin prophylaxis is used to prevent infections in children with sickle cell disease, but it is not a treatment for the anemia itself.

**Clinical Pearl / High-Yield Fact**
Remember that hydroxyurea is the only FDA-approved medication for the treatment of sickle cell anemia, and it should be initiated early in the course of the disease to maximize its benefits.

**Correct Answer: C. Penicillin prophylaxis is used to prevent infections in children with sickle cell disease, but it is not a treatment for the anemia itself.